Stock Earnings

Question 1

What are Canopus Biopharma Inc's key financial statements?

Accepted Answer

According to the latest financial statement (Form-10K), Semen Indonesia (Persero) Tbk PT has a total asset of $76,993,082, Net profit of $719,763

Question 2

What are the key financial ratios for CBIA?

Accepted Answer

Semen Indonesia (Persero) Tbk PT's Current ratio is 2.31, has a Net margin is 1.98, sales per share of $5,359.68.

Question 3

How is Canopus Biopharma Inc's revenue broken down by segment or geography?

Accepted Answer

Semen Indonesia (Persero) Tbk PT largest revenue segment is Cement, at a revenue of 28,244,714,000,000 in the most earnings release.For geography, Indonesia is the primary market for Semen Indonesia (Persero) Tbk PT, at a revenue of 34,337,132,000,000.

Question 4

Is Canopus Biopharma Inc profitable?

Accepted Answer

yes, according to the latest financial statements, Semen Indonesia (Persero) Tbk PT has a net profit of $719,763

Question 5

Does Canopus Biopharma Inc have any liabilities?

Accepted Answer

yes, Semen Indonesia (Persero) Tbk PT has liability of 33,221,562

Question 6

How many outstanding shares for Canopus Biopharma Inc?

Accepted Answer

Semen Indonesia (Persero) Tbk PT has a total outstanding shares of 6,751.54

Breakdown	TTM	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020
Revenue	35,195,899	36,186,127	38,651,360	36,378,597	36,702,301	35,171,668
Revenue Growth (YoY)	-6%	-6%	6%	-1%	4%	-13%
Cost of Revenue	28,291,243	28,255,001	28,474,383	25,700,993	24,975,639	23,554,567
Gross Profit	6,904,656	7,931,126	10,176,977	10,677,604	11,726,662	11,617,101
Selling, General & Admin	4,538,424	4,830,967	5,129,975	5,383,706	5,701,748	5,179,976
Research & Development	38,374	33,930	23,011	24,966	33,910	16,797
Operating Expenses	5,690,445	5,769,785	5,660,853	6,093,608	6,503,451	5,846,942
Other Non Operating Income (Expenses)	-34,558	-45,289	-80,770	-58,594	-49,040	-33,394
Pretax Income	560,440	1,251,199	3,303,760	3,298,835	3,537,704	3,488,650
Income Tax Expense	369,391	479,525	1,008,159	799,752	1,420,468	814,307
Net Income	114,877	719,763	2,170,497	2,364,836	2,046,692	2,792,321
Net Income Growth	-90%	-67%	-8%	16%	-27%	17%
Shares Outstanding (Diluted)	6,751.54	6,751.54	6,751.54	5,961.53	5,969.31	5,948
Shares Change (YoY)	0%	0%	13%	0%	0%	0%
EPS (Diluted)	17.01	106.6	321.48	396.68	342.86	469.45
EPS Growth	-90%	-67%	-19%	16%	-27%	17%
Free Cash Flow	2,543,977	2,778,178	3,992,967	4,165,356	5,150,117	5,935,269
Free Cash Flow Per Share	--	--	--	--	--	--
Gross Margin	19.61%	21.91%	26.33%	29.35%	31.95%	33.02%
Operating Margin	3.44%	5.97%	11.68%	12.6%	14.23%	16.4%
Profit Margin	0.32%	1.98%	5.61%	6.5%	5.57%	7.93%
Free Cash Flow Margin	7.22%	7.67%	10.33%	11.45%	14.03%	16.87%
EBITDA	1,865,196	2,794,797	5,179,246	5,238,982	5,896,938	6,413,722
EBITDA Margin	5.29%	7.72%	13.39%	14.4%	16.06%	18.23%
D&A For EBITDA	650,985	633,456	663,122	654,986	673,727	643,563
EBIT	1,214,211	2,161,341	4,516,124	4,583,996	5,223,211	5,770,159
EBIT Margin	3.44%	5.97%	11.68%	12.6%	14.23%	16.4%
Effective Tax Rate	65.91%	38.32%	30.51%	24.24%	40.15%	23.34%

Canopus Biopharma Inc (CBIA) Financial

CBIA Stock Price Chart

Key Stats

Prev.Close

Open

Day's Range

52 week range

Volume

Avg.Volume

Dividend yield

EPS (TTM)

Market Cap

What is CBIA?

CBIA Income

Follow-Up Questions